Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
-
December 23, 2024
Fujirebio and Eisai Enter into Memorandum of Understanding for
Joint Research and Social Implementation of Blood-based Biomarkers
in the Field of Neurodegenerative Diseases
-
December 11, 2024
鈥淯RECE庐鈥� (DOTINURAD) APPROVED IN CHINA FOR GOUT PATIENTS WITH HYPERURICEMIA
-
December 5, 2024
鈥淟EQEMBI庐鈥� (Lecanemab) Approved for the Treatment of Early Alzheimer鈥檚 Disease in Mexico
-
November 29, 2024
Eisai Announces Completion of Cancellation of Treasury Shares
Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act
-
November 28, 2024
鈥淟EQEMBI庐鈥� (Lecanemab) for the Treatment of Alzheimer鈥檚 Disease Launched in South Korea
-
November 26, 2024
EISAI SIGNS RESEARCH COLLABORATION AGREEMENT WITH THE NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY TO INITIATE APOLIPOPROTEIN E GENETIC TESTING IN THE 鈥淎D-DMT REGISTRY鈥� IN JAPAN
-
November 20, 2024
ROZEBALAMIN庐 FOR INJECTION 25 MG (MECOBALAMIN) FOR AMYOTROPHIC LATERAL SCLEROSIS LAUNCHED IN JAPAN
-
November 20, 2024
ANTICANCER AGENT 鈥淭ASFYGO庐 TABLETS 35mg鈥� (TASURGRATINIB SUCCINATE) LAUNCHED IN JAPAN FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSION OR REARRANGEMENTS
-
November 15, 2024
NATIONWIDE TV COMMERCIAL LAUNCHED IN JAPAN TO RAISE AWARENESS ABOUT MCI (MILD COGNITIVE IMPAIRMENT)
-
November 15, 2024
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer鈥檚 Disease
-
November 5, 2024
Eisai鈥檚 Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED鈥檚 鈥楽trengthening Program for Pharmaceutical Startup Ecosystem鈥�
-
November 1, 2024
Eisai Completes Rolling Submission to US FDA for LEQEMBI庐 (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer鈥檚 Disease Under the Fast Track Status
-
October 31, 2024
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer鈥檚 Disease (CTAD) Conference
-New testing method highlights link between protofibrils and biomarkers for neurodegeneration-
-Patient and caregiver perspectives on five-year treatment with lecanemab-
-Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD-
-
October 31, 2024
EISAI PRESENTS LATEST CLINICAL FINDINGS SUGGESTING INHIBITION OF TAU PROPAGATION BY ANTI-MTBR TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD)
Eisai Initiates Phase II Clinical Study on Sporadic Early Alzheimer's Disease
-
October 30, 2024
REVENUE OF LEQEMBI庐 (PRELIMINARY BASIS)
-
October 24, 2024
EISAI TO PRESENT UPDATED DUAL-ACTING LECANEMAB DATA, RESEARCH ON BLOOD BIOMARKERS FOR PREDICTING PRESENCE OF AMYLOID IN THE BRAIN AND NEW FINDINGS ON THE ANTI-MTBR (MICROTUBULE BINDING REGION) TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS FOR ALZHEIMER'S
-
October 17, 2024
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Demonstrating the Utility of Blood Biomarkers in Predicting Amyloid Beta Accumulation in the Brain
-
October 17, 2024
UPDATE ON REGULATORY REVIEW OF LECANEMAB FOR EARLY ALZHEIMER鈥橲 DISEASE IN AUSTRALIA
-
October 16, 2024
AMYOTROPHIC LATERAL SCLEROSIS TREATMENT 鈥淩OZEBALAMIN庐 FOR INJECTION 25 MG鈥� RECEIVES THE GOOD DESIGN AWARD 2024 FOR LIGHT-PROOF VIAL PACKAGING
-
October 8, 2024
鈥淯RECE庐 TABLETS鈥� (DOTINURAD) APPROVED IN THAILAND FOR GOUT AND HYPERURICEMIA
-
October 4, 2024
Eisai Announces Status and Completion of Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
October 2, 2024
EISAI COMMENCES BUSINESS ACTIVITIES AT NEW PHARMA SALES SUBSIDIARY IN SAUDI ARABIA
-
October 1, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
September 24, 2024
ROZEBALAMIN庐 FOR INJECTION 25 MG (MECOBALAMIN) APPROVED IN JAPAN FOR AMYOTROPHIC LATERAL SCLEROSIS
-
September 24, 2024
ANTICANCER AGENT 鈥淭ASFYGO庐 TABLETS 35mg鈥� (TASURGRATINIB SUCCINATE)
APPROVED IN JAPAN FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSIONS OR REARRANGEMENTS
-
September 17, 2024
RELEASE OF DEMENTIA DISEASE AWARENESS VIDEO FOR WORLD ALZHEIMER鈥橲 MONTH
鈥淭ODAY FOR TOMORROW鈥�: A DOCUMENTARY OF SIX MONTHS FOLLOWING THE CURRENT STATE OF DEMENTIA
鈥淟EARNING HELPS US TO BE KIND鈥�
-
September 17, 2024
LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
In the Phase 3 LEAP-012 trial, LENVIMA plus KEYTRUDA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone
Late-breaking first interim analysis results are being presented during a Presidential Symposium session at the European Society for Medical Oncology Congress 2024
-
September 12, 2024
Investigator-initiated clinical studies to be launched following confirmation of tumor shrinkage induced by the targeted protein degrader E7820 using J-PDX (Japanese cancer patient-derived tissue transplantation models)
Aiming to establish a drug discovery and development system that accelerates the development of new anticancer drugs
-
September 5, 2024
EISAI ACCELERATES PROGRESS IN ONCOLOGY RESEARCH WITH NEW DATA AT ESMO CONGRESS 2024
-
September 2, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
August 27, 2024
RELEASE OF INSOMNIA AWARENESS VIDEO FOR JAPAN鈥橲 AUTUMN SLEEP HEALTH WEEKS
-
August 22, 2024
Leqembi庐 (lecanemab) Authorized for Early Alzheimer鈥檚 Disease in Great Britain
In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer鈥檚 disease (AD) in adult patients that are apolipoprotein E 蔚4 (ApoE 蔚4)* heterozygotes or non-carriers
Great Britain becomes the first country in Europe to authorize the medicine, which targets an underlying cause of AD1
-
August 14, 2024
鈥淟EQEMBI庐鈥� (Lecanemab) Approved for the Treatment of Alzheimer鈥檚 Disease in the United Arab Emirates
-
August 6, 2024
Update Regarding the Regulatory Status of LEQEMBI庐 Subcutaneous Formulation
-
August 1, 2024
REVENUE OF LEQEMBI庐 (PRELIMINARY BASIS)
-
August 1, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
July 31, 2024
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI庐 (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer鈥檚 Disease Patients Presented at AAIC 2024
- 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
- Clinical Data and Biomarkers Show Alzheimer鈥檚 Disease Does Not Stop Progressing After Plaque Clearance. Lecanemab鈥檚 Dual Action Supports Neuronal Function by Clearing Highly Toxic Protofibrils that Continue to Cause Neuronal Injury and Death After Rapid Plaque Clearance
- Lecanemab Slows Tau Spread Across All Brain Regions
-
July 26, 2024
Update on Regulatory Review of Lecanemab for Early Alzheimer鈥檚 Disease in the European Union
-
July 24, 2024
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
-
July 23, 2024
EISAI TO PRESENT DUAL-ACTING LECANEMAB THREE YEAR EFFICACY AND SAFETY DATA AND DISCUSS LONG-TERM OUTCOMES OF CONTINUED TREATMENT AT THE ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE 2024
Latest findings from Eisai鈥檚 robust Alzheimer鈥檚 disease (AD) pipeline will be shared, including the importance of continued treatment of AD, which is a progressive neurodegenerative disease that begins before plaque deposition and continues after plaque removal
-
July 16, 2024
EISAI ENTERS INTO LICENSE AGREEMENT FOR FOSRAVUCONAZOLE IN ASIA/OCEANIA WITH SATO PHARMA
-
July 12, 2024
鈥淟EQEMBI庐鈥� (Lecanemab) Approved for the Treatment of Alzheimer鈥檚 Disease in Israel
-
July 11, 2024
EISAI LISTED FOR 23RD CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES,
AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
July 11, 2024
鈥淟EQEMBI庐鈥� (Lecanemab) Approved for the Treatment of Alzheimer鈥檚 Disease in Hong Kong
-
July 1, 2024
EISAI ANNOUNCES MOVE TO SOLO DEVELOPMENT AND COMMERCIALIZATION OF FARLETUZUMAB ECTERIBULIN (FZEC) ANTIBODY DRUG CONJUGATE (ADC)
Strategic collaboration with Bristol Myers Squibb ended
-
July 1, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
June 28, 2024
鈥淟EQEMBI庐鈥� (Lecanemab) for the Treatment of Alzheimer鈥檚 Disease Launched in China
China is the Third Country to Launch LEQEMBI Following the United States and Japan
-
June 27, 2024
Position and Policy Regarding Reduction of the Investment Unit of the Company's Shares
-
June 21, 2024
EISAI CONTINUES CONTRACT FOR FY2024 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY
ACHIEVEMENT OF OUTCOME INDICATORS IN FY2023 PAY FOR SUCCESS CONTRACT
-
June 14, 2024
Eisai Announces Appointments of Directors and Corporate Officers
-
June 10, 2024
FDA Accepts Eisai鈥檚 Filing of LEQEMBI庐 (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer鈥檚 Disease
-
June 3, 2024
EISAI NAMED TO LIST OF THE TIME 100 MOST INFLUENTIAL COMPANIES
-
June 3, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
June 3, 2024
EISAI STRENGTHENS VENTURE INVESTMENT BUSINESS AIMED AT ACCELERATING DRUG DISCOVERY INNOVATION AND ESTABLISHMENT OF ECOSYSTEM PLATFORM
-
May 27, 2024
鈥淟EQEMBI庐鈥� (Lecanemab) Approved for the Treatment of Alzheimer鈥檚 Disease in South Korea
-
May 23, 2024
EISAI SHOWCASES ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2024
-
May 22, 2024
METOJECT庐 SUBCUTANEOUS INJECTION PEN (METHOTREXATE) PEN-TYPE AUTOINJECTOR LAUNCHED IN JAPAN
-
May 15, 2024
Eisai Announces Acquisition of Own Shares and Cancellation of Treasury Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act and cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act
-
May 15, 2024
Notice of Nominees for Directors and Corporate Officers
-
May 15, 2024
Notice Concerning Appointment of New Representative Officer
-
May 15, 2024
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI庐 (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer鈥檚 Disease Under the Fast Track Status
-
May 13, 2024
ANTIEPILEPTIC DRUG FYCOMPA庐 APPROVED IN CHINA FOR ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
-
April 24, 2024
REVENUE OF LEQEMBI庐 (PRELIMINARY BASIS)
-
April 17, 2024
RESEARCH ON TREATMENTS FOR ALZHEIMER鈥橲 DISEASE BASED ON ITS PATHOLOGICAL MECHANISMS RECIEVES AWARD FOR SCIENCE AND TECHNOLOGY (RESEARCH CATEGORY), AS A PART OF FY2024 COMMENDATION FOR SCIENCE AND TECHNOLOGY BY MEXT
-
April 17, 2024
ANTIEPILEPTIC DRUG FYCOMPA庐 INJECTION FORMULATION LAUNCHED IN JAPAN
ADDRESSING MEDICAL NEEDS FOR PATIENTS WHO CANNOT TAKE THE MEDICATION ORALLY
-
April 11, 2024
EISAI SUPPORTS RELIEF EFFORTS FOR THE EARTHQUAKE OF THE EAST COAST OF TAIWAN
-
April 2, 2024
FRENCH SALES SUBSIDIARY EISAI S.A.S. TO DIVEST RIGHTS FOR LOXAPAC庐 AND PARKINANE庐 LP TO CNX THERAPEUTICS
-
April 1, 2024
Eisai Completes Submission of LEQEMBI庐 (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer鈥檚 Disease to the U.S. FDA
-
March 29, 2024
EISAI TO DIVEST RIGHTS FOR MERISLON庐 AND MYONAL庐 IN JAPAN TO KAKEN PHARMACEUTICAL
-
March 28, 2024
EISAI鈥橲 BRAIN HEALTH SELF-CHECK TOOL 鈥淣OUKNOW庐鈥� IS CERTIFIED AS 鈥淢E-BYO BRAND鈥� BY KANAGAWA PREFECTURE
-
March 28, 2024
DISCOVERY RESEARCH ON DUAL OREXIN RECEPTOR ANTAGONIST LEMBOREXANT HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 2024
-
March 25, 2024
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
-
March 22, 2024
DELIBERATIONS AT THE CHMP REGARDING THE MARKETING AUTHORIZATION APPLICATION IN THE EU FOR LECANEMAB HAVE BEEN RESCHEDULED DUE TO PROCEDURAL REASONS AT THE EUROPEAN MEDICINES AGENCY
-
March 21, 2024
Lifenet and Eisai Co-Develop Dementia Insurance 鈥渂e鈥�
Supporting early detection and treatment of dementia and mild cognitive impairment (MCI)
-
March 21, 2024
EISAI SELECTED AS A NADESHIKO BRAND 2024 AS A LISTED COMPANY EXCELLING IN PROMOTION OF WOMEN IN THE WORKPLACE
-
March 6, 2024
EISAI INVESTS IN C2N TO SUPPORT SIMPLIFYING THE DIAGNOSIS OF EARLY ALZHEIMER鈥橲 DISEASE TO BETTER SERVE PATIENTS
-
February 29, 2024
EISAI TO PRESENT DATA ON LECANEMAB AND OTHER ALZHEIMER鈥橲 DISEASE RESEARCH AT THE AD/PD鈩� 2024 ANNUAL MEETING
-
February 21, 2024
EISAI TO BOOST INITIATIVES ON GREENHOUSE GAS REDUCTION,AIMING TO ACHIEVE NET ZERO BY 2050
PARTICIPATION IN JCI RACE TO ZERO CIRCLE AND APPROVAL FOR SBT 1.5掳C TARGET
-
February 20, 2024
EISAI SELECTED FOR 鈥淗UMAN CAPITAL LEADERS 2023鈥� AND 鈥淗UMAN CAPITAL MANAGEMENT GOLD QUALITY鈥�, RECOGNIZED AS COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES
-
February 15, 2024
METOJECT庐 SUBCUTANEOUS INJECTION PEN (METHOTREXATE) PEN-TYPE AUTOINJECTOR APPROVED IN JAPAN
-
February 1, 2024
EISAI COMMENCES FULLY-FLEDGED BUSINESS ACTIVITIES AT PHARMA SALES SUBSIDIARY IN SOUTH AFRICA
COMMENCEMENT OF DIRECT SALES OPERATIONS IN AFRICA, AND ESTABLISHMENT OF BRANCH OFFICE IN KENYA
-
January 26, 2024
EISAI SUBMITS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRAHIGH-DOSE FORMULATION IN JAPAN FOR THE INDICATION OF AMYOTROPHIC LATERAL SCLEROSIS
-
January 18, 2024
ANTIEPILEPTIC DRUG FYCOMPA庐 INJECTION FORMULATION APPROVED IN JAPAN
ADDRESSING MEDICAL NEEDS FOR TREATMENT THROUGH A NON-ORAL ADMINISTRATION ROUTE
-
January 17, 2024
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE EIGHTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 16, 2024
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024
-
January 11, 2024
THE SCIENTIFIC ADVISORY GROUP (SAG) TO CONVENE TO DISCUSS THE MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB IN THE EU
-
January 9, 2024
鈥淟EQEMBI庐鈥� (Lecanemab) Approved for the Treatment of Alzheimer鈥檚 Disease in China
China is the Third Country to Approve LEQEMBI Following the United States and Japan
-
January 5, 2024
EISAI SUPPORTS RELIEF EFFORTS FOR THE NOTO PENINSULA EARTHQUAKE OF 2024 IN JAPAN
-
December 26, 2023
DEVELOPMENT OF PREDICTION MODEL FOR BRAIN AMYLOID-BETA ACCUMULATION USING WRISTBAND SENSOR
-
December 18, 2023
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TASURGRATINIB FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSION
-
December 13, 2023
Eisai and Mizuho Sign Sustainability-Linked Loan Agreement
-
December 13, 2023
鈥淟EQEMBI庐 Intravenous Infusion鈥� (Lecanemab) for the Treatment of Alzheimer鈥檚 Disease to be Launched in Japan on December 20
-
December 9, 2023
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
-
November 30, 2023
EISAI鈥橲 SALES SUBSIDIARY COLLABORATES WITH MINISTRY OF PUBLIC HEALTH (MOPH) IN THAILAND
-
November 22, 2023
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 77TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING
-
November 20, 2023
LEQEMBI庐 Wins Best New Drug And Clinical Advance Of The Year at The Scrip Awards 2023
-
November 16, 2023
EISAI NAMED AS 鈥淕REATEST IR IMPROVEMENT PREMIUM COMPANY鈥� AND 鈥淏EST CONTINUAL IR EFFORTS PREMIUM COMPANY鈥� AT THE JAPAN INVESTOR RELATIONS ASSOCIATION 30TH ANNIVERSARY COMMEMORATIVE AWARDS
-
October 26, 2023
EISAI PRESENTS NEW LEQEMBI庐 (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER鈥橲 DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER鈥橲 DISEASE (CTAD) CONFERENCE
INVESTIGATIONAL SUBCUTANEOUS FORMULATION CLEARS 14% MORE PLAQUE THAN IV, PHARMACOKINETICS (AUC) 11% HIGHER, AND SIMILAR ARIA RATES TO IV
76% OF PATIENTS SHOWED NO DECLINE AND 60% SHOWED CLINICAL IMPROVEMENT AT 18 MONTHS IN LOW-TAU SUBPOPULATION IN ADDITIONAL ANALYSIS OF CLARITY AD
DUAL-ACTING LEQEMBI SUPPORTS BRAIN NEURON FUNCTION BY REMOVING HIGHLY TOXIC PROTEINS (PROTOFIBRILS) THAT CAN CONTINUE TO CAUSE NEURONAL INJURY AND DEATH EVEN AFTER PLAQUE REMOVAL, OFFERING EARLY AD PATIENTS THE OPPORTUNITY FOR CONTINUED BENEFIT
-
October 25, 2023
LEQEMBI庐 (LECANEMAB-IRMB) NAMED ONE OF TIME鈥橲 BEST INVENTIONS OF 2023
-
October 16, 2023
EISAI TO PRESENT NEW DATA FROM LEQEMBI庐 (LECANEMAB-IRMB) PHASE 3 CLARITY AD STUDY AND OTHER ALZHEIMER鈥橲 DISEASE PIPELINE RESEARCH AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
Update on LEQEMBI Investigational Subcutaneous Formulation
-
October 11, 2023
EISAI TO PRESENT RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO CONGRESS 2023
-
October 4, 2023
Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
-
September 28, 2023
EISAI LAUNCHES NEW 鈥淚NNOVATION鈥� PAGE ON CORPORATE WEBSITE
-
September 28, 2023
TOKIO MARINE NICHIDO AND EISAI
CO-DEVELP INDUSTRY鈥橲 FIRST 鈥淒EMENTIA CARE SUPPORT INSURANCE鈥�
-
September 25, 2023
鈥淟EQEMBI庐 Intravenous Infusion鈥� (Lecanemab) Approved for the Treatment of Alzheimer鈥檚 Disease in Japan
-
September 22, 2023
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Two Phase 3 Trials Evaluating LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
-
September 21, 2023
RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMER鈥橲 DAY, SEPTEMBER 21
LIFE GOES ON 2023: TWO MEMORIES, ONE STORY
LEARNING HELPS US TO BE KIND
-
September 12, 2023
EISAI ESTABLISHES THEORIA TECHNOLOGIES CO., LTD., A NEW DIGITAL BUSINESS COMPANY TO BUILD A DEMENTIA ECOSYSTEM
-
August 25, 2023
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-010 Trial Evaluating LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
-
August 4, 2023
EISAI LISTED FOR 22ND CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
August 1, 2023
ORGANIZATIONAL REFORM AND CHANGES OF CORPORATE OFFICERS
-
July 20, 2023
Eisai Presents Latest Analysis of Lecanemab鈥檚 Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer鈥檚 Association International Conference (AAIC) 2023
Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer鈥檚 disease
New data on subcutaneous formulation shows promising PK /PD data modeling on efficacy and safety, representing a potential new option for administering therapy
-
July 12, 2023
EISAI TO PRESENT THE LATEST ALZHEIMER鈥橲 DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023
-
July 11, 2023
CHANGES OF CORPORATE OFFICERS
-
July 7, 2023
FDA Grants Traditional Approval for LEQEMBI庐 (lecanemab-irmb) for the Treatment of Alzheimer鈥檚 Disease
The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer鈥檚 disease
The Centers for Medicare & Medicaid Services (CMS) announced broader Medicare coverage of LEQEMBI
-
June 30, 2023
EISAI TRANSFERS ALL FUTURE ECONOMIC RIGHTS FOR ELACESTRANT, A SELECTIVE ESTROGEN RECEPTOR DEGRADER, TO DRI HEALTHCARE
-
June 29, 2023
Position and Policy Regarding Reduction of the Investment Unit of the Company's Shares
-
June 29, 2023
NEW NEURII RESEARCH COLLABORATION BETWEEN EISAI, GATES VENTURES, HEALTH DATA RESEARCH UK, LIFEARC AND THE UNIVERSITY OF EDINBURGH TO DEVELOP DIGITAL SOLUTIONS FOR DEMENTIA IS ANNOUNCED
-
June 22, 2023
EISAI鈥橲 鈥淣OUKNOW庐鈥� WILL CONTINUE TO BE UTILIZED FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2023 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY
ACHIEVEMENT OF OUTCOME INDICATORS IN FY2022 PAY FOR SUCCESS CONTRACT
-
June 10, 2023
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI庐 (lecanemab-irmb) for the Treatment of Alzheimer鈥檚 Disease
Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer鈥檚 disease
The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with designation of priority review
LEQEMBI received accelerated approval from the FDA for the treatment of early Alzheimer鈥檚 disease on January 6, 2023
-
June 8, 2023
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER鈥橲 DISEASE IN SOUTH KOREA
-
June 6, 2023
Notification of Ransomware Incident
-
June 2, 2023
EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 37TH ANNUAL SLEEP 2023 MEETING
-
May 26, 2023
LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
After four years of follow-up, LENVIMA plus KEYTRUDA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial
Final results will be presented at ASCO 2023 in an oral abstract session
-
May 25, 2023
EISAI鈥橲 INITIATIVES FOR DEVELOPING NEW MEDICINES FOR NEGLECTED TROPICAL DISEASES AND MALARIA AND COMMITMENT FOR FUNDING TO THE 3RD PHASE OF GLOBAL HEALTH INNOVATIVE TECHNOLOGY FUND ACTIVITIES
-
May 24, 2023
EISAI DELIVERS NEW DATA AND HIGHLIGHTS CONTINUED PROGRESS OF ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023
-
May 22, 2023
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER鈥橲 DISEASE IN GREAT BRITAIN
-
May 17, 2023
EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB IN JAPAN USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
-
May 16, 2023
HEALTH CANADA ACCEPTS NEW DRUG SUBMISSION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER鈥橲 DISEASE
-
May 15, 2023
Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Revision of the Stock Compensation System (Officers鈥� Compensation BIP Trust)
-
May 15, 2023
Notification Regarding the Revision of the Compensation System for Directors and Corporate Officers and Stock Compensation System (Officers鈥� Compensation BIP Trust) and Additional Contribution
-
May 9, 2023
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2023
-
May 8, 2023
EISAI ENTERS INTO JOINT DEVELOPMENT AGREEMENT WITH BLISSBIO FOR ANTIBODY DRUG CONJUGATE BB-1701 WITH OPTION RIGHTS FOR STRATEGIC COLLABORATION
-
April 7, 2023
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 Trials of LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) in Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)
-
April 6, 2023
EISAI COMPLETES A MAJOR RENOVATION OF TSUKUBA RESEARCH LABORATORIES
AS A GLOBAL DRUG DISCOVERY CENTER AIMING FOR CONNECTING HUMAN AND HUMAN, AND DATA, AND THE WORLD
-
April 4, 2023
EISAI PUBLISHES LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
Treatment with Lecanemab Resulted in a Delay of 2 to 3 Years in the Mean Time to Progression to More Severe Stages of Alzheimer鈥檚 Disease, Compared with Standard of Care Alone
Subgroup Analysis Suggested that Earlier Initiation of Treatment with Lecanemab May Have a Greater Impact on Disease Progression
-
April 3, 2023
EISAI ENTERS INTO AGREEMENT WITH NATIONAL CANCER CENTER TO COLLABORATE ON INVESTIGATOR-INITIATED CLINICAL RESEARCH FOR ANTICANCER AGENT TAZEMETOSTAT BASED ON 鈥淧ATIENT-PROPOSED HEALTHCARE SERVICES鈥� SYSTEM
-
March 31, 2023
EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD鈩� 2023 ANNUAL MEETING
-
March 31, 2023
ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS
-
March 24, 2023
EISAI TO PRESENT RESEARCH FROM ONCOLOGY PORTFOLIO AT THE SOCIETY OF GYNECOLOGIC ONCOLOGY (SGO) 2023 ANNUAL MEETING ON WOMEN鈥橲 CANCER
-
March 23, 2023
EISAI TO PRESENT NEW LECANEMAB DATA, INCLUDING RESEARCH EVALUATING SAFETY PROFILE, CLINICAL OUTCOMES AND QUALITY OF LIFE MEASURES, AS WELL AS OTHER IMPORTANT ALZHEIMER鈥橲 DISEASE RESEARCH, AT THE AD/PD鈩� 2023 ANNUAL MEETING
Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Patients from Eisai鈥檚 Lecanemab Phase 3 Confirmatory Clarity AD Study in Early Alzheimer鈥檚 Disease
-
March 20, 2023
EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
-
March 14, 2023
U.S. VETERANS鈥� HEALTH ADMINISTRATION (VHA) PROVIDES COVERAGE OF LEQEMBI鈩� (LECANEMAB-IRMB) TWO MONTHS AFTER LEQEMBI鈥橲 FDA ACCELERATED APPROVAL FOR VETERANS LIVING WITH EARLY STAGES OF ALZHEIMER鈥橲 DISEASE
EISAI IS PROUD TO SUPPORT U.S. VETERANS LIVING WITH EARLY STAGES OF ALZHEIMER鈥橲 DISEASE AND WILL CONTINUE TO TRANSPARENTLY SHARE OUR HIGH-QUALITY DATA WITH THE VHA
-
March 10, 2023
EISAI RECEIVES THE 鈥淏ASIC ACHIEVEMENT GRAND PRIZE鈥� AT THE 2023 J-WIN DIVERSITY AWARD
-
March 9, 2023
EISAI CERTIFIED AS A 2023 HEALTH AND PRODUCTIVITY MANAGEMENT OUTSTANDING ORGANIZATION (WHITE 500)
-
March 6, 2023
FDA Accepts Eisai鈥檚 Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI鈩� (lecanemab-irmb) for the Treatment of Alzheimer鈥檚 Disease
Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval
Priority Review accelerates FDA review time with a Prescription Drug User Fee Act (PDUFA) target action on July 6, 2023
-
March 2, 2023
BIOGEN JAPAN AND EISAI PROVIDE UPDATE ON CO-PROMOTION OF MULTIPLE SCLEROSIS TREATMENTS IN JAPAN
-
February 28, 2023
BIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION
-
February 20, 2023
DISSOLUTION OF BRACCO-EISAI JOINT VENTURE
-
January 30, 2023
LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN
-
January 27, 2023
MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER鈥橲 DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY
-
January 19, 2023
EISAI COMMENCES BUSINESS ACTIVITIES AT NEW PHARMA SALES SUBSIDIARY IN ISRAEL
-
January 18, 2023
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 18, 2023
EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023
Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal Cancer
Research from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information 爱豆传媒 Treating Patients with Unresectable Hepatocellular Carcinoma
-
January 16, 2023
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER鈥橲 DISEASE IN JAPAN
-
January 13, 2023
EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE
-
January 11, 2023
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER鈥橲 DISEASE IN EUROPE
-
January 7, 2023
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI鈩� (lecanemab-irmb) for the Treatment of Alzheimer鈥檚 Disease
Submission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and is based on data from the confirmatory Phase 3 Clarity AD clinical trial
-
January 7, 2023
Eisai鈥檚 Commitment to Scientific Evidence and Patient Safety
-
January 7, 2023
EISAI鈥橲 APPROACH TO U.S. PRICING FOR LEQEMBI鈩� (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER鈥橲 DISEASE, SETS FORTH OUR CONCEPT OF 鈥淪OCIETAL VALUE OF MEDICINE鈥� IN RELATION TO 鈥淧RICE OF MEDICINE鈥�
MAXIMIZING VALUE FOR ALL STAKEHOLDERS WHILE GIVING BACK VALUE TO SOCIETY
-
January 7, 2023
FDA Approves LEQEMBI鈩� (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer鈥檚 Disease
Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI鈩�
Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials
